Finance

Lists
EMCURE:NSE
Emcure Pharmaceuticals Ltd
₹2,348.00
+1.45%
(+33.60) 1D
Nov 13, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for EMCURE...
Open
₹2,325.00
High
₹2,395.00
Low
₹2,315.40
Mkt. cap
447.37B
Avg. vol.
229.26K
Volume
294.54K
Dividend
0.15%
Quarterly dividend
₹0.90
Ex-dividend date
Sep 4, 2026
P/E ratio
49.29
52-wk high
₹2,429.90
52-wk low
₹1,312.30
EPS
₹47.64
No. of employees
7K
Open
₹2,325.00
High
₹2,395.00
Low
₹2,315.40
Mkt. cap
447.37B
Avg. vol.
229.26K
Volume
294.54K
Dividend
0.15%
Quarterly dividend
₹0.90
Ex-dividend date
Sep 4, 2026
P/E ratio
49.29
52-wk high
₹2,429.90
52-wk low
₹1,312.30
EPS
₹47.64
No. of employees
7K
News stories
From web sources and news partners
Profile
Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals. Wikipedia
About Emcure Pharmaceuticals Ltd
CEOSatish Ramanlal Mehta
Employees6.91K
FoundedApr 16, 1981
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteemcure.com
Last report
Nov 3, 2026
Fiscal period
Q2 2027
₹17.14 / ₹14.90
+15.03%beat
Revenue / Est. (INR)
28.20B / 26.52B
+6.35%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
23.63B
24.70B
25.80B
28.20B
Cost of goods sold
9.62B
10.93B
10.73B
11.42B
Cost of revenue
9.62B
10.93B
10.73B
11.42B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.87B
7.21B
4.09B
4.35B
Operating expense
10.46B
9.97B
11.09B
12.13B
Total operating expenses
20.08B
20.90B
21.82B
23.55B
Operating income
3.55B
3.79B
3.98B
4.65B
Other non operating income
18.53M
-363.67M
20.71M
32.54M
EBT including unusual items
3.14B
3.41B
3.94B
4.46B
EBT excluding unusual items
3.52B
3.72B
3.92B
4.46B
Income tax expense
824.22M
974.40M
1.01B
1.21B
Effective tax rate
26.27%
28.56%
25.67%
27.09%
Other operating expenses
5.54B
1.70B
5.90B
6.69B
Net income
2.31B
2.43B
2.94B
3.26B
Net profit margin
9.75%
9.86%
11.39%
11.54%
Earnings per share
13.67
14.70
15.34
17.14
Interest and investment income
-
16.83M
-
-
Interest expense
-379.75M
-92.49M
-315.36M
-355.76M
Net interest expenses
-379.75M
-75.66M
-315.36M
-355.76M
Depreciation and amortization charges
1.05B
1.06B
1.10B
1.10B
EBITDA
4.37B
4.67B
5.02B
5.75B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps